Cellective Therapeutics, a biotech startup focused on treatments for cancer, lupus and arthritis, has closed on $27.5 million in venture capital.
Intersouth Partners of Durham led the round.
Other investors include Alta Partners, BA Venture Partners, Forward Ventures, Genentech, Inc., Latterell Venture Partners, MedImmune Ventures, Inc., and Sofinnova Ventures.
Cellective is a spinout of Duke University and has three employees.
Arthur Mandell has been named CEO of the firm as part of the funding. Mandell was president and CEO of Stemron. Prior to that position he served as senior vice president and chief business officer at Human Genome Sciences.
